BRNO, Czech Republic and SALEM, NH, USA – April 21, 2022: GeneProof a.s. (“GeneProof”), a leading molecular diagnostics company based in Brno, Czech Republic, today announced a merger with American Laboratory Products Company, Ltd. (“ALPCO”), a specialty in vitro diagnostics company. The combination creates a global market leader in the diagnostic products market, with broad capabilities spanning novel immunoassay testing kits, real-time PCR testing products, and automated laboratory instrumentation solutions.
The combined company is owned by Ampersand Capital Partners (“Ampersand”) as well as by the founders of GeneProof, Radek Horváth and Miloš Dendis.
“GeneProof and ALPCO have both earned great reputations in their respective markets, ALPCO in immunodiagnostics and GeneProof in molecular diagnostics,” said Sean Conley, President and CEO of ALPCO. “The combination of the two companies transforms both organizations into a more complete solutions provider and aligns well with ALPCO’s strategy of investing in proprietary automated platforms.”
Radek Horvath, CEO of GeneProof, added, “This strategic connection represents a new chapter in the life of both companies. It will facilitate the entry of GeneProof products into the US market, and similarly, expand the presence of ALPCO products into the EU and around the world. The combination of deep knowledge in the field of molecular diagnostics as well as in the field of immunological diagnostics will bring a significant synergistic effect. The two merged companies intend to use each other's technological experience and rely on the support of our strong partner, Ampersand, for further development.”
Eric Lev, General Partner at Ampersand and Board member of ALPCO added, “I look forward to working with Sean, Radek, and Milos as we build the combined company into a fully integrated global leader in the field of diagnostics and commercialize GeneProof’s fully automated real-time PCR offerings in the North American market.”
For more information go to GeneProof webpage.